Drugs in ATC Class N05CE

Up to Top Level ATC Classes

Up to N - Nervous system

Up to N05 - PSYCHOLEPTICS

Up to N05C - HYPNOTICS AND SEDATIVES

Drugs in ATC Class: N05CE - Piperidinedione derivatives

Tradename	Generic Name
DORIDEN	glutethimide
GLUTETHIMIDE	glutethimide
NOLUDAR	methyprylon

ATC N05CE Piperidinedione Derivatives: Market Dynamics and Patent Landscape for Key Branded Products, Exclusivity Timelines, and Generic/Biosimilar Entry Risks

Last updated: July 27, 2026

Piperidinedione derivatives under ATC class N05CE are dominated in practice by schizophrenia and related CNS indications that rely on branded oral agents. Patent coverage typically concentrates in (1) active pharmaceutical ingredient (API) and early process claims, (2) fixed-dose combinations or salt forms, (3) polymorphs/solid-state forms, and (4) formulation and method-of-use claims that support exclusivity extensions. Competitive pressure is usually driven by FDA generic substitution for small-molecule CNS products, with patent risk highest when the Orange Book lists composition-of-matter or method-of-use patents that remain in-force and when Paragraph IV certifications have been filed.

Which piperidinedione derivatives are in ATC Class N05CE and how does the patent estate differ by active ingredient?

Answer: The ATC N05CE “Piperidinedione derivatives” category is a small-molecule CNS group where patent estates are usually strongest around the original API and early solid-state/formulation generations. Later-life-cycle patents tend to cluster around polymorphs, grain-size/particle engineering, extended-release or dose form changes, and method-of-use expansions.

Common active ingredients in N05CE portfolios

The patent landscape depends on the specific branded API within N05CE. Typical piperidinedione derivatives used for CNS indications include:

• Perphenazine-like or other phenothiazines are not piperidinedione derivatives (these belong to other ATC groups), so N05CE coverage is not interchangeable across phenothiazines.
• Piperidinedione derivatives with antipsychotic activity are the relevant commercial anchors for this ATC class.

Patent estate pattern (small-molecule antipsychotics):

• Primary filings: API synthesis, salts, and stereochemical compositions.
• Secondary filings: polymorphs, solvates, hydrates, amorphous forms; solid-state characterization; crystallization processes.
• Formulation filings: tablet/capsule composition, excipient systems, granulation/drying, coating, and dissolution profiles.
• Method-of-use: dosing regimens, titration, comorbidity-linked indications, and sub-population language.
• Manufacturing: scalable and reproducible routes that avoid generic workarounds.

Why the estate structure matters for market dynamics

For CNS brands, revenue exposure generally hinges on:

• Whether Orange Book patents include composition-of-matter and method-of-use coverage that blocks safe harbor “skinny labels.”
• Whether the brand uses multiple continuation-family patents to maintain staggered expiration dates.
• Whether later-life-cycle patents survive obviousness challenges and can be asserted in litigation stays.

Practical outcome: When Orange Book lists multiple active patents, generic entry risk concentrates on the strongest remaining claims. When Orange Book listings are sparse or largely expires, the first Paragraph IV challenger typically captures the launch window.

What patents protect piperidinedione derivatives (API, formulations, and method of use) in the US?

Answer: For N05CE piperidinedione derivative brands that have US FDA approvals, the US patent estate typically includes: (1) API composition and salt/polymorph claims, (2) formulation composition claims tied to dosage form and dissolution behavior, and (3) method-of-use claims tied to dosing regimens and indications. The highest blocking power usually comes from active Orange Book patents that are not limited to a discontinued form factor.

Patent claim buckets that commonly show up in Orange Book filings

1. Composition of matter (API)

   • Core synthesis, salts, and stereoisomers.
   • Sometimes broad genus claims plus narrower examples.

2. Solid-state and polymorph patents

   • Unique polymorphs/solvates and crystallization steps.
   • These often matter for generic manufacturers seeking to use different crystal forms while staying within claim scope.

3. Formulation patents

   • Tablet/capsule formulations.
   • Particle size control, disintegration/dissolution targets, and excipient selections.
   • Coating and sustained-release engineering (if applicable).

4. Method-of-use patents

   • Indication-specific language.
   • Dosing schedule language (loading dose, titration).
   • Response or patient-subgroup linked claims.

How many patents cover piperidinedione derivatives?

Answer: The number varies by product and product life-cycle. The market-wide pattern for small-molecule CNS brands is a multi-patent portfolio with clustered filing years at launch plus continuation filings and formulation/polymorph additions. In practice, Orange Book coverage commonly spans multiple distinct expiration dates, not a single endpoint.

When does exclusivity end for N05CE piperidinedione derivatives (patent expiration vs regulatory exclusivity)?

Answer: Exclusivity is usually governed by a layered timeline: (1) regulatory exclusivity periods (five-year New Chemical Entity or three-year new clinical studies where applicable), (2) patent term expirations by family member, and (3) any pediatric extensions where granted. For established oral small molecules, patent term timing tends to dominate launch delay more than regulatory exclusivity.

Timeline framework used to forecast generic entry

• Regulatory exclusivity end: depends on application type and whether the drug is an NCE, new indication, or supplement.
• Primary composition-of-matter expiration: often the longest clock anchor.
• Secondary patents: polymorph/formulation/method-of-use can create late-stage barriers.
• Litigation-triggered stays: for Paragraph IV, a first filer and subsequent settlements can delay FDA approval or launch.

What is the Orange Book status of piperidinedione derivatives and how many in-force patents block generic substitution?

Answer: Orange Book status is the decisive gating item: the presence of in-force patents (especially composition-of-matter and method-of-use) can force generics into Paragraph IV challenges or skinny-label carve-outs.

What to look for on Orange Book entries

• Active status by patent number (expiration dates).
• Patent type codes: composition, method-of-use, and formulation.
• Listing tie-ins: whether listed patents cover the same dosage form strength that is being sought by the generic.

Market impact of Orange Book density

• Dense listings typically produce a higher likelihood of litigation.
• Sparse listings shift the market dynamic toward faster entry and price compression.

Which companies are challenging piperidinedione derivatives with Paragraph IV filings?

Answer: Paragraph IV filing activity in this class usually comes from large US generics and specialty challengers seeking first-to-file exclusivity. The market dynamic turns on whether challenges target (1) composition-of-matter claims that cannot be designed around or (2) method-of-use claims that can be avoided via labeling.

How to predict challenge strategy

• If Orange Book lists method-of-use only and composition patents are expired, challengers often file to carve out indications.
• If composition or key formulation/polymorph patents are in force, challengers usually target claim scope and seek design-arounds or generic launches under licensing.

What patent litigation affects piperidinedione derivatives and how do settlement agreements change launch timing?

Answer: Litigation settlements typically convert a contested launch date into a contractual delay with potential royalty or market-share terms. For CNS small molecules, settlements often cover:

• Earlier-than-expected generic entry limits during remaining patent life.
• Stipulated dismissal after payment or agreed launch date.
• Scope restrictions on dosage forms/strengths.

Common settlement structures in US generic CNS

• Launch date in exchange for dismissal of infringement.
• No-early-entry clauses linked to specific patent expiry.
• Geographic scope typically US only, with parallel foreign settlements sometimes pursued.

What formulations are protected for piperidinedione derivatives, and what manufacturing/IP barriers exist for generics?

Answer: Formulation protection is frequently targeted by generics that attempt to replicate the brand’s dissolution and exposure profile. Barriers are highest when formulation patents cover:

• Specific excipient combinations and processing steps.
• Granulation/drying and coating methods that drive dissolution behavior.
• Particle size, polymorph selection, or in-process controls tied to solid-state identity.

Typical design-around paths and failure modes

• Polymorph change: may fail if claims capture polymorph genus or specific characteristics.
• Salt change: may fail if salt forms are captured or if bioequivalence requirements force same form use.
• Process redesign: may fail if process claims are infringed by the end product or if courts find equivalence.

How do piperidinedione derivative product lifecycles compare across key brands in N05CE?

Answer: Most piperidinedione antipsychotic brands follow a three-stage lifecycle:

1. Initial API and early solid-state coverage.
2. Formulation and method-of-use continuation families during years 5 to 12 post-approval.
3. Final-stage litigation and settlement as generics test claims near expiration.

Market consequence: price and share shifts around the last blocking patent

When the final blocking patent expires or is settled:

• Generics usually gain formulary share quickly due to substitution and cost pressure.
• Brand sales typically decline unless the brand introduces a reformulated product with independent protection.

Biosimilar risk: do N05CE piperidinedione derivatives face biosimilar competition?

Answer: No. Biosimilar frameworks apply to biologics, not these small-molecule piperidinedione derivatives. Competitive risk comes from small-molecule generics and authorized generics, not biosimilars.

What generic entry risks exist for piperidinedione derivatives (design-arounds, skinny labels, and authorized generics)?

Answer: Generic entry risks are defined by three levers:

1. Whether generics can avoid method-of-use patents via labeling carve-outs.
2. Whether generics can design around polymorph/formulation patents without losing bioequivalence.
3. Whether settlement and exclusivity terms delay entry even after patent expiry.

Launch scenario matrix

• Low risk: no in-force patents or only expired composition patents; method-of-use patents absent or easily carved out.
• Medium risk: method-of-use patents in force; likely skinny-label route.
• High risk: active composition/polymorph/formulation patents; likely Paragraph IV litigation or licensing.

Commercial exposure: how sensitive are N05CE piperidinedione derivative revenues to patent expiry?

Answer: Exposure is highest where:

• The brand has limited reformulation options.
• Orange Book lists multiple remaining patents with staggered expiration dates.
• The drug is a core therapy in formulary formularies and faces limited alternative switching.

What drives revenue at risk (RAtR)

• Remaining patent life on composition and key formulation.
• US-only vs global exclusivity synchronization (foreign litigation can affect US strategy).
• Whether the brand has authorized generic pathways.

What is the competitive landscape for N05CE piperidinedione derivatives (branded vs generic vs authorized generic)?

Answer: Competition typically evolves from branded dominance to a generic-dominant market following the expiration or settlement of the strongest Orange Book patents. Authorized generics often cap price erosion and preserve a portion of market share and margins for the brand holder.

Typical post-expiration dynamics

• First generic launches: margin compression, fast share capture.
• Subsequent generics: continued price reductions; formulary consolidation.
• Brand response: reformulation or lifecycle extension with separate patent protection.

---

Key Takeaways

• N05CE “piperidinedione derivatives” is a small-molecule CNS category where patent estates usually hinge on API composition, solid-state (polymorph/salt), formulation/dissolution, and method-of-use claims.
• Generic entry timing is dominated by Orange Book in-force listings and Paragraph IV litigation or settlements, not biosimilar risk.
• Formulation and polymorph patents are frequent late-life blockers because they constrain design-arounds while maintaining bioequivalence.
• Market dynamics show staged erosion after the final blocking patent expires, often with authorized generics smoothing the transition.

---

FAQs

1. How do Orange Book method-of-use patents affect skinny-label generic approval for N05CE piperidinedione derivatives?
2. What claim scope in polymorph and solid-state patents most often blocks generic piperidinedione derivatives?
3. Do settlements in US Paragraph IV cases for CNS small molecules typically include license terms or only launch-date provisions?
4. Which formulation elements (excipients, particle size, dissolution profile) are most targeted for N05CE generic design-arounds?
5. How should investors model revenue at risk for CNS piperidinedione derivatives around the last Orange Book expiration?

---

References (APA)

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
2. U.S. Food and Drug Administration. FDA Drug Approval Reports and review documents for relevant N05CE piperidinedione derivative approvals. FDA.
3. U.S. Food and Drug Administration. Hatch-Waxman exclusivity and patent listing guidance. FDA.